Malaria Vaccine Development Unit (mvdu)

疟疾疫苗开发股(MVDU)概述：由Louis Miller博士领导的疟疾疫苗开发股(MVDU)是NIAID为应对全球对疟疾疫苗的需求而发起的一项新倡议。在过去一年里，由于国际开发署主任安东尼·福奇博士对这一问题的关注，以及比尔和梅林达·盖茨基金会宣布支持疟疾，进一步推动了这一努力。MVDU于5月6日在安东尼·福奇博士主持的仪式上正式开幕。我们正在开始生产cGMP蛋白，包括明年开始的疫苗试验配方。MVDU主要关注来自疟疾寄生虫发育的无性血液阶段和有性阶段的重组蛋白。对血液阶段的免疫主要是为了减少与疟疾有关的病理，而对性阶段的免疫则是为了减少通过蚊子媒介的传播，并在世界上传播率较低的某些地区消除感染。为了实现这些目标，MVDU拥有在各种重组系统中表达蛋白质以及随后的纯化和分析的设施。一些蛋白质的生产过程已经完成，它们将用于人体试验。临床级材料的工艺开发和生产现在是优先事项。整个装置现已改造为工业型实验室，实行工业型质量控制制度。我们现在正在加强在美国和马里进行临床试验的组成部分。

Malaria Vaccine Development Unit (MVDU) General Description: The Malaria Vaccine Development Unit (MVDU) headed by Dr. Louis Miller is a new NIAID initiative to respond to the global need for vaccines against malaria. This effort has been given additional impetus during the past year by the attention focused on this issue by Dr. Anthony Fauci, Director, NIAID, and by support for malaria announced by the Bill and Melinda Gates Foundation. The MVDU opened officially on May 6 at a ceremony hosted by Dr. Anthony Fauci. We are beginning to produce cGMP proteins and including formulations for vaccine trials that should start next year. The MVDU is focusing primarily on recombinant proteins derived from asexual blood stages and sexual stages of malaria parasite development. Immunity to the blood stages would primarily be designed to reduce pathology associated with malaria while immunity to the sexual stages would be designed to reduce transmission via the mosquito vector and eliminate the infection in certain parts of the world where transmission is low. To accomplish these goals, the MVDU has facilities for protein expression in a variety of recombinant systems as well as subsequent purification and analysis. The process for some proteins has been completed, and they are produced for human trials. The process development and production of clinical grade material is now a priority. The whole unit is now converted to an industrial type lab with the institution of industrial type control on quality. We are now strengthening the component for clinical trials both in the US and in Mali.